Novavax Q4 revenue $291M, full-year net loss $545M; guides 2024 revenue $800M-$1B

NOVAVAX INC

2023-FY EPS reported -$5.41 revenue$983,705,000

Q4 2023 revenue $291M (down 18% YoY); full-year revenue $984M (down 51% from $2B in 2022).
Full-year 2023 net loss $545M vs $658M in 2022; operating expenses cut 41% ($1.1B reduction).
Cash $584M at Dec 31, 2023, down from $1.3B a year earlier; raised $110M via ATM offerings in Q4.
FY2024 guidance: total revenue $800M-$1B, combined R&D+SG&A $700-$800M; Q1 2024 revenue expected ~$100M.
Announced Gavi settlement; plan to start Phase 3 COVID-flu combo trial in H2 2024 with potential 2026 launch.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

NOVAVAX INC updated its the fourth quarter and twelve months ended December 31, 2023 guidance (reaffirmed).

Period: the fourth quarter and twelve months ended December 31, 2023
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On February 28, 2024, Novavax, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended December 31, 2023.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

NOVAVAX INC filing history →

Source: SEC EDGAR

accession 0001000694-24-000009

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.